Chemours (CC)
(Delayed Data from NYSE)
$19.65 USD
-0.11 (-0.56%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $19.87 +0.22 (1.12%) 7:58 PM ET
4-Sell of 5 4
C Value F Growth B Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$19.65 USD
-0.11 (-0.56%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $19.87 +0.22 (1.12%) 7:58 PM ET
4-Sell of 5 4
C Value F Growth B Momentum D VGM
Zacks News
FMC Corp (FMC) to Post Q1 Earnings: What's in the Cards?
by Zacks Equity Research
FMC Corp's (FMC) first-quarter performance is likely to reflect increased demand and pricing amid headwinds from higher input costs resulting from supply chain disruptions.
Westlake (WLK) to Post Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Westlake's (WLK) Q1 performance is likely to have benefited from higher demand trends for polyethylene and PVC resin.
Will Higher Selling Prices Drive Mosaic's (MOS) Q1 Earnings?
by Zacks Equity Research
Profitability across Mosaic's (MOS) Phosphates and Potash segments is expected to have boosted by higher average selling prices in Q1.
Intrepid Potash (IPI) to Post Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Intrepid Potash (IPI) is likely to have benefited from strong demand and higher net realized sales price per ton for its potash and Trio products in Q1.
Nutrien (NTR) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Nutrien's (NTR) Q1 results are likely to have benefited from solid demand and higher prices for fertilizers, aided by the underlying strength in global agriculture markets.
Chemours (CC) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Chemours (CC) closed at $32.64, marking a +1.15% move from the previous day.
LyondellBasell (LYB) to Post Q1 Earnings: What's in the Cards?
by Zacks Equity Research
LyondellBasell's (LYB) Q1 performance is likely to have benefited from strong consumer-driven demand and favorable market trends.
Chemours (CC) to Post Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Chemours' (CC) first-quarter performance is likely to reflect the increasing adoption of Opteon refrigerants and the benefits of cost-cutting measures.
Mosaic (MOS) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Mosaic (MOS) is likely to have benefited from strong demand and prices for phosphate and potash in the first quarter.
Huntsman (HUN) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Huntsman's (HUN) Q1 performance is likely to have benefited from health demand and prices for MDI amid headwinds from higher input and logistics costs.
Celanese (CE) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Celanese's (CE) Q1 performance is likely to have benefited from productivity actions, investments in high-return organic projects and strategic acquisitions.
Linde (LIN) Gears Up to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
Higher industrial production is likely to have aided Linde (LIN) in Q1.
Chemours (CC) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Chemours (CC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Chemours (CC) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Chemours (CC) closed at $35.65 in the latest trading session, marking a +0.85% move from the prior day.
Chemours (CC) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Chemours (CC) closed at $32.44 in the latest trading session, marking a +0.43% move from the prior day.
Northern Technologies (NTIC) Q2 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Northern Technologies (NTIC) delivered earnings and revenue surprises of -33.33% and 4.84%, respectively, for the quarter ended February 2022. Do the numbers hold clues to what lies ahead for the stock?
Chemours (CC) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Chemours (CC) closed at $32.32 in the latest trading session, marking a +0.19% move from the prior day.
Chemours (CC) is a Top-Ranked Growth Stock: Should You Buy?
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Chemours (CC) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Chemours (CC) closed the most recent trading day at $32.18, moving +1.71% from the previous trading session.
Chemours (CC) is a Top-Ranked Value Stock: Should You Buy?
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Chemours (CC) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Chemours (CC) closed at $30.55 in the latest trading session, marking a +0.03% move from the prior day.
Chemours (CC) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Chemours (CC) closed the most recent trading day at $29.17, moving +1.14% from the previous trading session.
Chemours (CC) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Chemours (CC) closed at $25.88, marking a +1.61% move from the previous day.
Chemours (CC) is a Top-Ranked Growth Stock: Should You Buy?
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Chemours (CC) Earnings Miss Estimates, Revenues Top in Q4
by Zacks Equity Research
Volumes and prices contributed favorably to Chemours' (CC) top-line growth in the fourth quarter. It sees adjusted earnings per share in the band of $4.07-$4.70 for 2022.